Market research
GEKA.F Genomma Lab Internacional, S.A.B. de C.V
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 616M
- P/E ratio
- 7.88
- Analyst target
- 23.53
- Dividend yield
- 62.%
- Beta
- 0.12
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- MX01LA010006
- Market cap
- 616M
- P/E ratio
- 7.88
- Analyst target
- 23.53
- Dividend yield
- 62.%
- Beta
- 0.12
About
About Genomma Lab Internacional, S.A.B. de C.V
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and improvement products, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, infant nutrition, and others. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the GEKA.F discussion.
5 years, 5 months ago
Genomma Lab Internacional, S.A.B. de C.V is currently in a long term uptrend where the price is trading 2.3% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.5.
Genomma Lab Internacional, S.A.B. de C.V's total revenue rose by 6.4% to $3B since the same quarter in the previous year.
Its net income has increased by 1048.0% to $409M since the same quarter in the previous year.
Finally, its free cash flow grew by 996.4% to $803M since the same quarter in the previous year.
Based on the above factors, Genomma Lab Internacional, S.A.B. de C.V gets an overall score of 5/5.